18889881171
Kalkine 0
countryflagUS

bioAffinity Technologies Inc. Warrant

Healthcare US BIAFW

0.1295USD
-(-%)

Last update at 2025-05-19T20:00:00Z

Day Range

0.130.13
LowHigh

52 Week Range

0.052.90
LowHigh

Fundamentals

  • Previous Close 0.13
  • Market Cap0.00000M
  • Volume100
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-8.03455M
  • Revenue TTM7.32M
  • Revenue Per Share TTM0.74
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -7.91602M -8.15165M -6.32446M -7.26599M -3.30430M
Minority interest - - - - -
Net income -7.93701M -8.15411M -6.32641M -7.26874M -3.30750M
Selling general administrative 6.79M 2.73M 0.88M 0.99M -
Selling and marketing expenses - - - - -
Gross profit 0.54M 0.00434M -0.00482M -0.02224M -0.04028M
Reconciled depreciation 0.11M 0.01M 0.00482M 0.02M -
Ebit -7.97323M -4.01106M -2.20682M -2.60439M -3.09224M
Ebitda -7.72364M -5.82109M -1.47665M -6.86157M -3.05196M
Depreciation and amortization 0.25M -1.81003M 0.73M -4.25719M 0.04M
Non operating income net other - - - - -
Operating income -7.97323M -4.01106M -2.20682M -2.60439M -3.09224M
Other operating expenses 10.51M 4.02M 2.21M 2.60M 3.09M
Interest expense 0.04M 2.53M 1.00M 0.38M 0.21M
Tax provision 0.02M 0.00246M 0.00195M 0.00275M -
Interest income 0.15M 0.05M 0.00042M 0.00107M -
Net interest income 0.05M -2.48593M -1.00143M -0.38110M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.02M 0.00246M 0.00195M 0.00275M 0.00320M
Total revenue 2.53M 0.00480M 0.00131M 0.00000M -
Total operating expenses 8.52M 4.02M 2.21M 2.60M 3.05M
Cost of revenue 1.99M 0.00047M 0.00482M 0.02M 0.04M
Total other income expense net 0.06M -4.14060M -4.11764M -4.66160M -0.21206M
Discontinued operations - - - - -
Net income from continuing ops -7.23843M -8.15411M -6.32641M -7.26874M -
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 8.22M 12.18M 1.45M 0.15M 0.66M
Intangible assets 0.83M - - - -
Earning assets - - - - -
Other current assets 0.32M 0.12M 0.00422M 0.00566M 0.04M
Total liab 3.37M 1.14M 17.24M 15.22M 4.69M
Total stockholder equity 4.86M 11.04M -15.79072M -15.07286M -4.03554M
Deferred long term liab - - - - -
Other current liab 1.15M 0.54M 1.60M 0.98M 0.58M
Common stock 0.07M 0.06M 0.02M 0.02M 0.02M
Capital stock 0.07M 0.06M 0.02M 0.02M -
Retained earnings -44.60448M -36.66747M -28.51336M -22.18694M -14.91821M
Other liab - - - - -
Good will 1.40M - - - -
Other assets - - - - -
Cash 2.82M 11.41M 1.36M 0.08M 0.58M
Cash and equivalents - - - - -
Total current liabilities 2.25M 1.14M 13.04M 11.12M 4.69M
Current deferred revenue 0.03M - - - -
Net debt -1.24293M -11.16201M 10.00M 9.92M 3.43M
Short term debt 0.46M 0.25M 11.20M 9.95M 4.01M
Short long term debt - 0.25M 11.20M 9.95M -
Short long term debt total 1.58M 0.25M 11.36M 10.01M 4.01M
Other stockholder equity 49.39M -12134.47276M 12.70M 7.10M 6.84M
Property plant equipment - - - - -
Total current assets 3.97M 11.96M 1.44M 0.12M 0.62M
Long term investments - - - - -
Net tangible assets - - - - -
Short term investments - - - - -
Net receivables 0.81M 0.01M 0.00153M 0.00153M 0.00153M
Long term debt - - 0.16M 0.05M -
Inventory 0.02M 0.00554M 0.07M 0.03M -
Accounts payable 0.60M 0.35M 0.23M 0.19M 0.10M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -0.01872M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.02M 0.00600M 0.01M 0.02M 0.01M
Deferred long term asset charges - - - - -
Non current assets total 4.25M 0.22M 0.02M 0.03M 0.04M
Capital lease obligations 1.58M - - - -
Long term debt total - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -2.44283M -0.21999M 0.00000M -0.00289M -
Change to liabilities - - - - -
Total cashflows from investing activities - - - - -
Net borrowings - - - - -
Total cash from financing activities -0.34498M 14.34M 3.33M 1.72M 2.33M
Change to operating activities - - - - -
Net income -7.93701M -8.15411M -6.32641M -7.26874M -3.30750M
Change in cash -8.59219M 10.05M 1.28M -0.49538M -0.16659M
Begin period cash flow 11.41M 1.36M 0.08M 0.58M 0.75M
End period cash flow 2.82M 11.41M 1.36M 0.08M 0.58M
Total cash from operating activities -6.03781M -4.07085M -2.04898M -2.20764M -2.49020M
Issuance of capital stock 0.00000M 6.03M 0.00000M - -
Depreciation 0.25M 0.01M 0.00482M 0.02M 0.04M
Other cashflows from investing activities - - - - -
Dividends paid - 0.00018M - - -
Change to inventory -0.01294M -0.00554M 0.00000M - -
Change to account receivables 0.31M -0.00896M - - 0.00029M
Sale purchase of stock - -0.00018M - - -
Other cashflows from financing activities -0.34498M 9.01M 6.83M 3.43M -0.01140M
Change to netincome - - - - -
Capital expenditures 0.02M 0.22M 0.00000M 0.00289M 0.01M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.90M 0.11M 0.63M 0.48M 0.32M
Stock based compensation 0.75M 0.25M 0.04M 0.28M -
Other non cash items 0.96M 3.71M -0.24435M 4.28M 0.58M
Free cash flow -6.06071M -4.29083M -2.04898M -2.21053M -2.50160M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
BIAFW
bioAffinity Technologies Inc. Warrant		 - -% 0.13 - - - -
TMO
Thermo Fisher Scientific Inc		 -0.22 0.05% 411.84 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 -0.475 0.24% 195.63 29.09 28.01 5.67 3.20 6.00 19.09
A
Agilent Technologies Inc		 -0.69 0.61% 113.08 34.36 26.39 6.59 7.14 6.78 23.56
IDXX
IDEXX Laboratories Inc		 1.85 0.36% 519.95 49.99 45.66 11.29 27.85 11.46 34.46

Reports Covered

Stock Research & News

View All

Profile

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.

bioAffinity Technologies Inc. Warrant

22211 West Interstate 10, San Antonio, TX, United States, 78257

Key Executives

Name Title Year Born
Ms. Maria Zannes J.D. Founder, Pres, CEO & Director 1956
Dr. Vivienne I. Rebel M.D., Ph.D. Exec. VP and Chief Medical & Science Officer 1965
Mr. Michael Edwards CPA, M.B.A. Chief Financial Officer 1967
Mr. Xavier T. Reveles M.S. VP of Operations NA
Mr. Timothy P. Zannes J.D. Exec. VP, Sec. & Gen. Counsel 1953
Dr. William Bauta Ph.D. Sr. VP of Therapeutics NA
Mr. Steven Girgenti Founder & Executive Chairman of the Board 1946
Ms. Maria Zannes J.D. Founder, President, CEO & Director 1956
Mr. Michael Dougherty C.P.A., M.B.A. VP & CFO 1979
Mr. Xavier T. Reveles M.S. Chief Operating Officer 1970

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.